Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
224 people get CLVS articles and Market Currents by email alert.
Get email alerts on CLVS »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
Business Wire (May 16, 2013)
-
Business Wire (May 8, 2013)
-
Business Wire (May 7, 2013)
-
Business Wire (Apr 23, 2013)
-
Business Wire (Feb 28, 2013)
-
Business Wire (Feb 25, 2013)
-
Business Wire (Jan 7, 2013)
-
Business Wire (Jan 2, 2013)
-
Business Wire (Nov 12, 2012)
-
-
Business Wire (Nov 8, 2012)
-
-
Business Wire (Nov 5, 2012)
-
Business Wire (Oct 18, 2012)
To learn more about Seeking Alpha Pro, click here.
-
Clovis Oncology Raises $130 Million In IPOThe Burrill Report • Thu, Nov 17, 2011 -
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Tracking IPO PerformanceBespoke Investment Group • Fri, Mar 9, 2012 -
-
-
-
9 IPOs Planned For This WeekRenaissance Capital IPO Research • Tue, Nov 15, 2011
-
Business Wire (May 16, 2013)
-
Business Wire (May 8, 2013)
-
Business Wire (May 7, 2013)
-
Business Wire (Apr 23, 2013)
-
Business Wire (Feb 28, 2013)
-
Business Wire (Feb 25, 2013)
-
Business Wire (Jan 7, 2013)
-
Business Wire (Jan 2, 2013)
-
at MarketWatch.com (Nov 12, 2012)
-
at CNBC.com (Nov 12, 2012)
-
Business Wire (Nov 12, 2012)
-
Business Wire (Nov 8, 2012)
-
Business Wire (Nov 5, 2012)
-
Business Wire (Oct 18, 2012)
-
Business Wire (Aug 29, 2012)
-
at Fox Business (Aug 17, 2012)
-
at Fox Business (Aug 17, 2012)
-
at Fox Business (Aug 17, 2012)
-
at Fox Business (Aug 17, 2012)
CLVS vs. ETF Alternatives
Company Description
Currently, there's no company description for CLVS.
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Tuesday, May 7, 8:27 AM Clovis Oncology (CLVS): Q1 EPS of -$0.60 in-line. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Friday, March 1, 2:23 AM Clovis Oncology (CLVS): Q4 EPS of -$0.81 beats by $0.03. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Monday, November 12, 2012, 12:45 PM Midday top 10 gainers: TIE +42%. STV +32%. MYRX +18%. CPSS +17%. PZZI +15%. SRPT +13%. EVI +13%. JEF +12%. GILD +12%. CXS +12%. Midday top 10 Losers: CLVS -33%. GALE -33%. STSI -23%. RECV -17%. BZH -15%. ET -14%. XIDE -13%. NKTR -12%. MEET -12%. IDN -11%. Comment!
-
Monday, November 12, 2012, 9:10 AM
Premarket gainers: TIE +43%. JEF +24%. MYRX +17%. CXS +15%. GILD +12%. CELG +10%. SVNT +7%. SQNM +7%. LUK +7%. RIMM +6%. NKTR +6%. STV +5%. DNDN +5%. CEL +5%. PCP +5%.
Losers: CLVS -41%. STSI -20%. NBG -11%. Comment! [On the Move] - Monday, November 12, 2012, 8:39 AM Clovis Oncology (CLVS) shares collapse 42% after its CO-101 treatment failed to prolong the survival of patients with pancreatic cancer vs gemcitabine in a phase III study. Clovis is now ending the development of the drug pending further evaluation of the trial data. Comment! [Healthcare, On the Move]
- Wednesday, August 8, 2012, 6:33 AM Clovis Oncology (CLVS): Q2 EPS of -$0.61 in-line. (PR) Comment! [Earnings, Healthcare]
- Thursday, March 8, 2012, 11:00 AM Recent IPO Clovis Oncology (CLVS -9.8%) takes a hit after posting a $14.9M Q4 loss, despite showing improvement over the prior year period. Bottom line margins were hit as R&D expenses nearly doubled due to the expanded development activities for its CO-101 and CO-1686 drugs, as well as the in-licensing of Rucaparib from Pfizer in mid 2011. Comment! [Healthcare, Earnings, On the Move]